Posted by Michael Wonder on 25 Jan 2022
Vyepti (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults
24 January 2022 - Vyepti is the first intravenous treatment approved for migraine prevention in Europe.
Lundbeck announced that the European Commission has granted marketing authorisation for Vyepti (eptinezumab) in the European Union for the prophylactic treatment of migraine in adults who have at least four migraine days per month.
